Venture Life Group PLC Investor Presentation (2439Q)
25 Febbraio 2021 - 8:00AM
UK Regulatory
TIDMVLG
RNS Number : 2439Q
Venture Life Group PLC
25 February 2021
25 February 2021
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Company")
Investor Presentation
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the self-care market is pleased to
announce that Jerry Randall (CEO), Sharon Daly (Chief Commercial
Officer) and Andrew Waters (CFO) will provide a live presentation
relating to their full year results for the year ended 31(st)
December 2020 via the Investor Meet Company platform on 29th Mar
2021 at 1:00pm BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet VENTURE LIFE GROUP PLC via:
https://www.investormeetcompany.com/venture-life-group-plc/register-investor
Investors who already follow Venture Life Group on the Investor
Meet Company platform will automatically be invited.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
+44 (0) 20 7397
Cenkos Securities plc (Nomad and Joint Broker) 8900
Michael Johnson / Russell Kerr (Sales)
Stephen Keys / Camilla Hume (Corporate Finance)
+44 (0) 20 7496
N+1 Singer (Joint Broker) 3000
Jonathan Dighe (Sales)
Shaun Dobson / Carlo Spingardi (Corporate Finance)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, The
Netherlands and Italy, the Group's product portfolio includes some
key products such as the UltraDEX and Dentyl oral care product
ranges, food supplements for maintaining brain function, medical
devices for women's intimate healthcare, fungal infections and
proctology, and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEASALAALFEFA
(END) Dow Jones Newswires
February 25, 2021 02:00 ET (07:00 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024